CA3226178A1 - Gdf15 fusion proteins and uses thereof - Google Patents

Gdf15 fusion proteins and uses thereof Download PDF

Info

Publication number
CA3226178A1
CA3226178A1 CA3226178A CA3226178A CA3226178A1 CA 3226178 A1 CA3226178 A1 CA 3226178A1 CA 3226178 A CA3226178 A CA 3226178A CA 3226178 A CA3226178 A CA 3226178A CA 3226178 A1 CA3226178 A1 CA 3226178A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
fusion protein
gdf15
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226178A
Other languages
English (en)
French (fr)
Inventor
Jiangyu YAN
Rongbo CAO
Lin Xiao
Junnan ZENG
Limei Huang
Xiling WEI
Zhaofeng Li
Qingwei GONG
Xingguo Yan
Jing Li
Danxia HUANG
Xiaofeng Chen
Wenjia LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CA3226178A1 publication Critical patent/CA3226178A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3226178A 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof Pending CA3226178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110977378.7 2021-08-24
CN202110977378 2021-08-24
PCT/CN2022/114096 WO2023025120A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CA3226178A1 true CA3226178A1 (en) 2023-03-02

Family

ID=85321545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226178A Pending CA3226178A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Country Status (8)

Country Link
US (3) US20240350588A1 (cg-RX-API-DMAC7.html)
EP (3) EP4393941A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532882A (cg-RX-API-DMAC7.html)
KR (1) KR20240049337A (cg-RX-API-DMAC7.html)
CN (3) CN115925982A (cg-RX-API-DMAC7.html)
AU (1) AU2022333099A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226178A1 (cg-RX-API-DMAC7.html)
WO (3) WO2023025120A1 (cg-RX-API-DMAC7.html)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374454B1 (ko) * 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
CN105102618B (zh) * 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EP3027647A4 (en) * 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
US12054527B2 (en) * 2018-04-09 2024-08-06 Amgen Inc. Growth differentiation factor 15 fusion proteins
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
BR112021021271A2 (pt) * 2019-04-23 2021-12-21 Lg Chemical Ltd Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15
BR112022007128A2 (pt) * 2019-10-15 2022-07-05 Dragonfly Therapeutics Inc Ligação de proteínas nkg2d, cd16 e flt3
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CA3171363A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
EP4458863A1 (en) * 2021-12-31 2024-11-06 Sunshine Lake Pharma Co., Ltd. Fusion protein of glp-1 and gdf15 and use thereof

Also Published As

Publication number Publication date
US20240350588A1 (en) 2024-10-24
EP4393941A4 (en) 2025-10-15
AU2022333099A1 (en) 2024-02-08
KR20240049337A (ko) 2024-04-16
CN115925982A (zh) 2023-04-07
EP4393941A1 (en) 2024-07-03
WO2023025120A1 (en) 2023-03-02
JP2024532882A (ja) 2024-09-10
CN115925983A (zh) 2023-04-07
CN115925984A (zh) 2023-04-07
EP4393940A1 (en) 2024-07-03
WO2023025129A1 (zh) 2023-03-02
EP4392461A4 (en) 2025-10-15
EP4393940A4 (en) 2025-10-15
US20240391971A1 (en) 2024-11-28
EP4392461A1 (en) 2024-07-03
WO2023025123A1 (zh) 2023-03-02
US20240343770A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
EP2697257B1 (en) Fc fusion proteins comprising novel linkers or arrangements
JP2024020405A (ja) 神経ペプチドy受容体の調節因子としての抗体結合環状ペプチドチロシンチロシン化合物
AU2020200329A1 (en) Stabilization of Fc-containing polypeptides
US8871907B2 (en) Glycosylated immunoglobulin and immunoadhesin comprising the same
CN108570109A (zh) 包含免疫球蛋白Fc部分的双靶点融合蛋白
KR20190026684A (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
US20250179142A1 (en) Fusion protein of glp-1 and gdf15 and use thereof
US20240343770A1 (en) Gdf15 fusion proteins and uses thereof
CN116948037A (zh) 一种新结构长效卵泡刺激素重组蛋白及其制备和应用
CN114621353A (zh) 一种重组融合蛋白及其应用
CA2469724A1 (en) Mutant glycoproteins
WO2025252023A1 (en) Modulators for gipr, glp1r and/or gcgr and uses thereof
CN116948036A (zh) 重组孕马血清促性腺激素及其制备方法和应用
AU2005209571A1 (en) Methods and compostions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250630

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250630

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260623

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260724

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260724

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260727

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260727